NA
SGMT icon

NewEdge Advisors’s Sagimet Biosciences SGMT Stock Holding History

NewEdge Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.59K Buy
+1,070
New +$5.96K ﹤0.01% 3559
2025
Q2 		– Sell
-32,290
Closed -$105K – 4134
2025
Q1 		$105K Buy
+32,290
New +$135K ﹤0.01% 2279

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NewEdge Advisors's SGMT Position: Q1 2026 in Review

NewEdge Advisors opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 1,070 shares worth $5.59K. The stake represents ﹤0.01% of the portfolio and ranks #3559 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in SGMT as recently as Q1 2025.

NewEdge Advisors first reported a position in SGMT in Q1 2025 and has held it in 2 quarters since. The position peaked at $105K in Q1 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • NewEdge Advisors held 1,070 shares of Sagimet Biosciences worth $5.59K as of Q1 2026.
  • Sagimet Biosciences was a new NewEdge Advisors position in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3559 holding.
  • NewEdge Advisors first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 2 quarters since.
  • NewEdge Advisors's Sagimet Biosciences position peaked at $105K in Q1 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.